SM
ADPT icon

SB Management’s Adaptive Biotechnologies ADPT Stock Holding History

SB Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,240,000
Closed -$50.7M – 31
2021
Q2 		$50.7M Buy
+1,240,000
New +$48.2M 0.6% 11

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SB Management's ADPT Position: Q3 2021 in Review

SB Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 1,240,000 shares — an estimated $50.7M sold.

SB Management first reported a position in ADPT in Q2 2021 and held it in 1 quarter. The position peaked at $50.7M in Q2 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • SB Management reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • SB Management sold 1,240,000 Adaptive Biotechnologies shares in Q3 2021, an estimated $50.7M.
  • SB Management first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 1 quarter.
  • SB Management's Adaptive Biotechnologies position peaked at $50.7M in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on SB Management's 13F filing for Q3 2021, filed 12 Nov 2021.